Cite
MLA Citation
Manmeet Ahluwalia et al.. “ATIM-40. CIRCULATING MYELOID-DERIVED SUPPRESSOR CELLS PREDICT FAVORABLE RESPONSE TO IMMUNE CHECKPOINT THERAPY IN A RANDOMIZED TRIAL OF NIVOLUMAB AND BEVACIZUMAB IN RECURRENT GBM.” Neuro-oncology, vol. 21, n.d., p. vi10. http://access.bl.uk/ark:/81055/vdc_100101669209.0x000044